{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:42:02Z","timestamp":1790476922016,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08073-2","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:53:26Z","timestamp":1778169206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenomic-guided prescribing and polypharmacy across age groups in obsessive-compulsive disorder: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sheldon R.","family":"Garrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Zoghbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Weisensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline M.","family":"Hartig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maharaj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreya","family":"Vadapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"12","key":"8073_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.biopsych.2020.01.006","volume":"87","author":"B Mahjani","year":"2020","unstructured":"Mahjani B, Klei L, Hultman CM, Larsson H, Devlin B, Buxbaum JD, et al. Maternal effects as causes of Risk for Obsessive-compulsive disorder. Biol Psychiatry. 2020;87(12):1045\u201351. https:\/\/doi.org\/10.1016\/j.biopsych.2020.01.006.","journal-title":"Biol Psychiatry"},{"key":"8073_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/B978-0-444-64076-5.00049-1","volume":"148","author":"TV Fernandez","year":"2018","unstructured":"Fernandez TV, Leckman JF, Pittenger C. Genetic susceptibility in obsessive-compulsive disorder. Handb Clin Neurol. 2018;148:767\u201381.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"8073_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.9758\/cpn.2022.20.2.240","volume":"20","author":"F Kurhan","year":"2022","unstructured":"Kurhan F, Alp HH, Isik M, Atan YS. The evaluation of Thiol\/Disulfide homeostasis and oxidative DNA damage in patients with Obsessive compulsive disorder. Clin Psychopharmacol Neurosci. 2022;20(2):240\u201347. https:\/\/doi.org\/10.9758\/cpn.2022.20.2.240.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"8073_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40360-021-00534-6","volume":"22","author":"F Hadi","year":"2021","unstructured":"Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2021;22(1):69. https:\/\/doi.org\/10.1186\/s40360-021-00534-6.","journal-title":"BMC Pharmacol Toxicol"},{"key":"8073_CR5","unstructured":"American Psychiatric Association A. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA, USA: American Psychiatric Press, Inc; 2007."},{"issue":"2","key":"8073_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1461145702002900","volume":"5","author":"S Pallanti","year":"2002","unstructured":"Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharm. 2002;5(2):181\u201391. https:\/\/doi.org\/10.1017\/S1461145702002900.","journal-title":"Int J Neuropsychopharm"},{"issue":"1","key":"8073_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","volume":"227","author":"NA Fineberg","year":"2015","unstructured":"Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, et al. Obsessive\u2013compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res. 2015;227(1):114\u201325. https:\/\/doi.org\/10.1016\/j.psychres.2014.12.003.","journal-title":"Psychiatry Res"},{"issue":"3","key":"8073_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1056\/NEJMcp031002","volume":"350","author":"MA Jenike","year":"2004","unstructured":"Jenike MA. Obsessive\u2013compulsive disorder. N Engl J Med. 2004;350(3):259\u201365. https:\/\/doi.org\/10.1056\/NEJMcp031002.","journal-title":"N Engl J Med"},{"issue":"1","key":"8073_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/pgs.11.133","volume":"13","author":"EJ Brandl","year":"2012","unstructured":"Brandl EJ, Muller DJ, Richter MA. Pharmacogenetics of Obsessive\u2013compulsive disorders. Pharmacogenomics. 2012;13(1):71\u201381. https:\/\/doi.org\/10.2217\/pgs.11.133.","journal-title":"Pharmacogenomics"},{"issue":"13","key":"8073_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1017\/S0033291721001744","volume":"51","author":"B Mahjani","year":"2021","unstructured":"Mahjani B, Bey K, Boberg J, Burton C. Genetics of obsessive-compulsive disorder. Psychol Med. 2021;51(13):2247\u201359. https:\/\/doi.org\/10.1017\/S0033291721001744.","journal-title":"Psychol Med"},{"issue":"1","key":"8073_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatry. 2010;15(1):53\u201363. https:\/\/doi.org\/10.1038\/mp.2008.94.","journal-title":"Mol Psychiatry"},{"key":"8073_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fpsyt.2011.00070","volume":"2","author":"S Pallanti","year":"2011","unstructured":"Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive\u2013compulsive disorder comorbidity: clinical Assessment and therapeutic implications. Front Psychiatry. 2011;2:70. https:\/\/doi.org\/10.3389\/fpsyt.2011.00070.","journal-title":"Front Psychiatry"},{"issue":"5","key":"8073_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaac.2022.10.001","volume":"62","author":"HJ Walter","year":"2023","unstructured":"Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, et al. Clinical Practice guideline for the Assessment and treatment of children and adolescents with major and persistent depressive disorders. J Am Acad Child Psy. 2023;62(5):479\u2013502. https:\/\/doi.org\/10.1016\/j.jaac.2022.10.001.","journal-title":"J Am Acad Child Psy"},{"issue":"10","key":"8073_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaac.2020.05.005","volume":"59","author":"HJ Walter","year":"2020","unstructured":"Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, et al. Clinical Practice guideline for the Assessment and treatment of children and adolescents with Anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107\u201324. https:\/\/doi.org\/10.1016\/j.jaac.2020.05.005.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"8073_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.7326\/0003-4819-149-10-200811180-00007","volume":"149","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Clinical efficacy Assessment subcommittee of American College of P: using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of physicians. Ann Intern Med. 2008;149(10):725\u201333. https:\/\/doi.org\/10.7326\/0003-4819-149-10-200811180-00007.","journal-title":"Ann Intern Med"},{"issue":"6","key":"8073_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/mp.2010.138","volume":"16","author":"C McCabe","year":"2011","unstructured":"McCabe C, Mishor Z, Filippini N, Cowen PJ, Taylor MJ, Harmer CJ. SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex. Mol Psychiatry. 2011;16(6):592\u201394. https:\/\/doi.org\/10.1038\/mp.2010.138.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"8073_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/ajh\/hpv047","volume":"28","author":"BE Cohen","year":"2015","unstructured":"Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, Anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295\u2013302. https:\/\/doi.org\/10.1093\/ajh\/hpv047.","journal-title":"Am J Hypertens"},{"key":"8073_CR18","doi-asserted-by":"publisher","unstructured":"Kim AM, Salstein L, Goldberg JF. A systematic review of complex polypharmacy in bipolar disorder: prevalence, clinical features, adherence, and preliminary recommendations for practitioners. J Clin Psychiatry. 2021;82(3). https:\/\/doi.org\/10.4088\/JCP.20r13263.","DOI":"10.4088\/JCP.20r13263"},{"issue":"1","key":"8073_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40266-023-01076-8","volume":"41","author":"N Prasad","year":"2024","unstructured":"Prasad N, Lau ECY, Wojt I, Penm J, Dai Z, Tan ECK. Prevalence of and Risk factors for drug-Related readmissions in older adults: a systematic review and meta-analysis. Drugs Aging. 2024;41(1):1\u201311. https:\/\/doi.org\/10.1007\/s40266-023-01076-8.","journal-title":"Drugs Aging"},{"issue":"1","key":"8073_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2045125311430110","volume":"2","author":"P Grech","year":"2012","unstructured":"Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Ther Adv Psychopharmacol. 2012;2(1):5\u201311. https:\/\/doi.org\/10.1177\/2045125311430110.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"8073_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-244X-8-19","volume":"8","author":"B Zhu","year":"2008","unstructured":"Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008;8(1):19. https:\/\/doi.org\/10.1186\/1471-244X-8-19.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"8073_CR22","first-page":"555","volume":"25","author":"AM Vyas","year":"2019","unstructured":"Vyas AM, Kogut SJ. Aroke H: real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States. J Manag Care Spec Pharm. 2019;25(5):555\u201365.","journal-title":"J Manag Care Spec Pharm"},{"key":"8073_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","volume":"252","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Rosenheck RA. Psychotropic polypharmacy reconsidered: between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. J Affect Disord. 2019;252:450\u201357. https:\/\/doi.org\/10.1016\/j.jad.2019.04.018.","journal-title":"J Affect Disord"},{"issue":"5","key":"8073_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1176\/appi.ajp.20220446","volume":"180","author":"H Taipale","year":"2023","unstructured":"Taipale H, Tanskanen A, Tiihonen J. Safety of antipsychotic polypharmacy versus Monotherapy in a nationwide cohort of 61, 889 patients with schizophrenia. Am J Psychiatry. 2023;180(5):377\u201385. https:\/\/doi.org\/10.1176\/appi.ajp.20220446.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"8073_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs Monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499\u2013507. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4320.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"8073_CR26","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3390\/jcm12103389","volume":"12","author":"WM Bezabhe","year":"2023","unstructured":"Bezabhe WM, Radford J, Salahudeen MS, Bindoff I, Ling T, Gee P, et al. Ten-year trends in psychotropic prescribing and polypharmacy in Australian General Practice patients with and without dementia. J Clin Med. 2023;12(10):3389. https:\/\/doi.org\/10.3390\/jcm12103389.","journal-title":"J Clin Med"},{"issue":"1","key":"8073_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.psc.2022.11.003","volume":"46","author":"JJ Crowley","year":"2023","unstructured":"Crowley JJ. Genomics of Obsessive-compulsive disorder and Related disorders: what the clinician needs to know. Psychiatr Clin N Am. 2023;46(1):39\u201351. https:\/\/doi.org\/10.1016\/j.psc.2022.11.003.","journal-title":"Psychiatr Clin N Am"},{"issue":"3","key":"8073_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.psychres.2015.07.032","volume":"229","author":"LM Walden","year":"2015","unstructured":"Walden LM, Brandl EJ, Changasi A, Sturgess JE, Soibel A, Notario JF, et al. Physicians\u2019 opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015;229(3):913\u201318. https:\/\/doi.org\/10.1016\/j.psychres.2015.07.032.","journal-title":"Psychiatry Res"},{"issue":"1","key":"8073_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical Pharmacogenetics implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor Antidepressants. Clin Pharma Ther. 2023;114(1):51\u201368. https:\/\/doi.org\/10.1002\/cpt.2903.","journal-title":"Clin Pharma Ther"},{"issue":"01\/02","key":"8073_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(01\/02):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492.","journal-title":"Pharmacopsychiatry"},{"key":"8073_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","volume":"111","author":"JF Greden","year":"2019","unstructured":"Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59\u201367. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.003.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"8073_CR32","first-page":"26","volume":"17","author":"R Taj","year":"2005","unstructured":"Taj R, Khan S. A study of reasons of non-compliance to psychiatric treatment. J Ayub Med Coll Abbottabad. 2005;17(2):26\u201328.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"8073_CR33","doi-asserted-by":"publisher","unstructured":"Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12(2):e0170905. https:\/\/doi.org\/10.1371\/journal.pone.0170905.","DOI":"10.1371\/journal.pone.0170905"},{"key":"8073_CR34","doi-asserted-by":"publisher","unstructured":"Ghanbarian S, Wong GWK, Bunka M, Edwards L, Cressman S, Conte T, et al. Cost-effectiveness of pharmacogenomic-guided treatment for major depression. CMAJ. 2023;195(44):E1499\u2013508. https:\/\/doi.org\/10.1503\/cmaj.221785.","DOI":"10.1503\/cmaj.221785"},{"issue":"8","key":"8073_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.18553\/jmcp.2018.24.8.726","volume":"24","author":"EJ Groessl","year":"2018","unstructured":"Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm. 2018;24(8):726\u201334. https:\/\/doi.org\/10.18553\/jmcp.2018.24.8.726.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"8073_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cpt.2315","volume":"110","author":"R Zanardi","year":"2021","unstructured":"Zanardi R, Manfredi E, Montrasio C, Colombo C, Serretti A, Fabbri C. Pharmacogenetic-guided treatment of depression: real-world clinical applications, challenges, and perspectives. Clin Pharma Ther. 2021;110(3):573\u201381. https:\/\/doi.org\/10.1002\/cpt.2315.","journal-title":"Clin Pharma Ther"},{"key":"8073_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/7854_2020_205","volume":"49","author":"G Zai","year":"2021","unstructured":"Zai G. Pharmacogenetics of Obsessive-compulsive disorder: an evidence-Update. Curr Top Behav Neurosci. 2021;49:385\u201398.","journal-title":"Curr Top Behav Neurosci"},{"key":"8073_CR38","doi-asserted-by":"publisher","unstructured":"Zhang L, Tholkes AJ, Jones KC, Yang LJ, Sieger GK, Cullen KR, et al. Real-world characterization of psychiatric Pharmacogenomic test ordering and clinical relevance in adults and children. Clin Transl Sci. 2025;18(10):e70297. https:\/\/doi.org\/10.1111\/cts.70297.","DOI":"10.1111\/cts.70297"},{"key":"8073_CR39","doi-asserted-by":"publisher","first-page":"113017","DOI":"10.1016\/j.psychres.2020.113017","volume":"290","author":"RC Shelton","year":"2020","unstructured":"Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, Dunlop BW, et al. Combinatorial Pharmacogenomic algorithm is predictive of citalopram and Escitalopram metabolism in patients with major depressive disorder. Psychiatry Res. 2020;290:113017. https:\/\/doi.org\/10.1016\/j.psychres.2020.113017.","journal-title":"Psychiatry Res"},{"issue":"7","key":"8073_CR40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1176\/appi.ajp.20230657","volume":"181","author":"ML Baum","year":"2024","unstructured":"Baum ML, Widge AS, Carpenter LL, McDonald WM, Cohen BM, Nemeroff CB. American psychiatric Association Workgroup on B, novel T: pharmacogenomic clinical support tools for the treatment of depression. Am J Psychiatry. 2024;181(7):591\u2013607. https:\/\/doi.org\/10.1176\/appi.ajp.20230657.","journal-title":"Am J Psychiatry"},{"key":"8073_CR41","doi-asserted-by":"publisher","unstructured":"Garrison S, Schweinert S, Boyer M, Singh M, Vadapalli S, Engelmann J, et al. Polypharmacy and pharmacogenomics in high-acuity behavioral health care for autism spectrum disorder: a retrospective study. Child Adolesc Psychiatry Ment Health. 2025;19(1). https:\/\/doi.org\/10.1186\/s13034-025-00915-3.","DOI":"10.1186\/s13034-025-00915-3"},{"issue":"3","key":"8073_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s10578-021-01148-z","volume":"53","author":"JR Anderson","year":"2022","unstructured":"Anderson JR, Killian M, Fuller A, Hughes JL, Byerly M, Lindow J, et al. Psychometric evaluation of the Pediatric Quality of life Enjoyment and Satisfaction Questionnaire in a General youth population. Child Psychiatry Hum Dev. 2022;53(3):546\u201353. https:\/\/doi.org\/10.1007\/s10578-021-01148-z.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"2","key":"8073_CR43","first-page":"321","volume":"29","author":"J Endicott","year":"1993","unstructured":"Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321\u201326.","journal-title":"Psychopharmacol Bull"},{"issue":"11","key":"8073_CR44","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"8073_CR45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006\u201311.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"8073_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item Quick Inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u201383. https:\/\/doi.org\/10.1016\/S0006-3223(02)01866-8.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"8073_CR47","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","volume":"36","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, et al. Children\u2019s Yale-Brown Obsessive compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844\u201352. https:\/\/doi.org\/10.1097\/00004583-199706000-00023.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"8073_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jocrd.2011.12.002","volume":"1","author":"CA Conelea","year":"2012","unstructured":"Conelea CA, Schmidt ER, Leonard RC, Riemann BC, Cahill S. The Children\u2019s Yale\u2013Brown Obsessive compulsive Scale: clinician versus self-report format in adolescents in a residential treatment facility. J Educ Chang Obsessive-Compuls Relat Disord. 2012;1(2):69\u201372. https:\/\/doi.org\/10.1016\/j.jocrd.2011.12.002.","journal-title":"J Educ Chang Obsessive-Compuls Relat Disord"},{"key":"8073_CR49","doi-asserted-by":"publisher","unstructured":"Cheng AL, Downs DL, Brady BK, Hong BA, Park P, Prather H, et al. Interpretation of PROMIS depression and Anxiety measures compared with DSM-5 diagnostic criteria in musculoskeletal patients. JBJS Open Access. 2023;8(1). https:\/\/doi.org\/10.2106\/JBJS.OA.22.00110.","DOI":"10.2106\/JBJS.OA.22.00110"},{"key":"8073_CR50","unstructured":"Team, RC. R: a language and environment for Statistical Computing. In. R version 4.3.3 edn. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"issue":"8","key":"8073_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Soft. 2011;42(8):1\u201328. https:\/\/doi.org\/10.18637\/jss.v042.i08.","journal-title":"J Stat Soft"},{"issue":"1","key":"8073_CR52","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12888-023-04756-2","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry. 2023;23(1):334. https:\/\/doi.org\/10.1186\/s12888-023-04756-2.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"8073_CR53","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/gtmb.2011.0327","volume":"16","author":"DJ Muller","year":"2012","unstructured":"Muller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, et al. The AmpliChip \u00ae CYP450 test and response to treatment in schizophrenia and Obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarker. 2012;16(8):897\u2013903. https:\/\/doi.org\/10.1089\/gtmb.2011.0327.","journal-title":"Genet Test Mol Biomarker"},{"issue":"2","key":"8073_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/tpj.2013.12","volume":"14","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 2014;14(2):176\u201381. https:\/\/doi.org\/10.1038\/tpj.2013.12.","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"8073_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/pgs-2017-0015","volume":"18","author":"JT Brown","year":"2017","unstructured":"Brown JT, Schneiderhan M, Eum S, Bishop JR. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017;18(7):601\u201305. https:\/\/doi.org\/10.2217\/pgs-2017-0015.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"8073_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","volume":"175","author":"MM Jukic","year":"2018","unstructured":"Jukic MM, Haslemo T, Molden E. Impact of CYP2C19 genotype on escitalopram Exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018;175(5):463\u201370. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17050550.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"8073_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1229.104497","volume":"11","author":"S Kukreja","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82\u201399.","journal-title":"Mens Sana Monogr"},{"issue":"3","key":"8073_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/10408363.2019.1678568","volume":"57","author":"CN Sharp","year":"2019","unstructured":"Sharp CN, Linder MW, Valdes R Jr. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution. Crit Rev Clin Lab Sci. 2019;57(3):161\u201380.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"8073_CR59","doi-asserted-by":"publisher","first-page":"1365751","DOI":"10.3389\/fmed.2024.1365751","volume":"11","author":"D Garfinkel","year":"2024","unstructured":"Garfinkel D, Levy Y. Optimizing clinical outcomes in polypharmacy through poly-de-prescribing: a longitudinal study. Front Med. 2024;11:1365751. https:\/\/doi.org\/10.3389\/fmed.2024.1365751.","journal-title":"Front Med"},{"issue":"1","key":"8073_CR60","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12877-022-03388-7","volume":"22","author":"M Delara","year":"2022","unstructured":"Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Correction: prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):742. https:\/\/doi.org\/10.1186\/s12877-022-03388-7.","journal-title":"BMC Geriatr"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08073-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:53:01Z","timestamp":1783047181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08073-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8073"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08073-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8182802\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Rogers Behavioral Health Institutional Review Board (approved protocol number: RBH-2023\u201301). The study was designed in accordance with the Helsinki Declaration. This retrospective study utilized de-identified data, and a HIPAA (Health Insurance Portability and Accountability Act) waiver of informed consent was approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}